LogicBio Therapeutics Inc. (LOGC) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Comparison side by side

LogicBio Therapeutics Inc. (NASDAQ:LOGC) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR), both competing one another are Biotechnology companies. We will compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LogicBio Therapeutics Inc. N/A 0.00 18.20M -0.66 0.00
Citius Pharmaceuticals Inc. N/A 0.00 13.17M -1.06 0.00

Table 1 highlights LogicBio Therapeutics Inc. and Citius Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
LogicBio Therapeutics Inc. 0.00% 0% 0%
Citius Pharmaceuticals Inc. 0.00% -54.2% -48.3%

Liquidity

LogicBio Therapeutics Inc.’s Current Ratio and Quick Ratio are 5.7 and 5.7 respectively. The Current Ratio and Quick Ratio of its competitor Citius Pharmaceuticals Inc. are 1.8 and 1.8 respectively. LogicBio Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Citius Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors owned 65.1% of LogicBio Therapeutics Inc. shares and 5% of Citius Pharmaceuticals Inc. shares. Insiders owned 5.6% of LogicBio Therapeutics Inc. shares. Comparatively, Citius Pharmaceuticals Inc. has 44.4% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
LogicBio Therapeutics Inc. -3.04% 8.26% -31.05% 0% 0% -7.98%
Citius Pharmaceuticals Inc. 6.03% 28.13% 3.36% -16.33% -64.76% 18.27%

For the past year LogicBio Therapeutics Inc. has -7.98% weaker performance while Citius Pharmaceuticals Inc. has 18.27% stronger performance.

Summary

LogicBio Therapeutics Inc. beats Citius Pharmaceuticals Inc. on 4 of the 6 factors.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. has a partnership with Children's Medical Research Institute (CMRI) of Australia to develop new viral vectors. The company was founded in 2014 and is based in Cambridge, Massachusetts.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.